Future growth expectations in earnings/operating earnings/profits/EPS?

Archean Chemical Industries Limited expects healthy growth in FY '25, particularly from the Bromine segment, driven by stable demand and long-term contracts. Revenue from the new Phase 1 bromine derivatives is anticipated between INR 200 to 300 crores, expecting to reach the higher end by year-end. The Oren Hydrocarbon subsidiary is forecasted to contribute conservatively between INR 100 to 250 crores in FY '25, with potential upside based on market conditions and ramp-up. The company targets approximately 30% volume growth for FY '25 over FY '24, supported by expansion in bromine deriva

Any current/future new fundraising through debt or equity?

The management mentioned that the money for Phase 2 capex, especially for the FR-related project, has already been raised and is available with the company. They have taken a pause on committing further capex for Phase 2 to time it correctly according to market conditions. There is no indication of immediate new fundraising through debt or equity in the current call. The company is focusing on utilizing the capex already spent on Phase 1 and expanding the product portfolio within that. Further capital expenditures will be assessed based on market developments and product pricing, with no expli

Any current/future capex/capital investment/strategic investment?

Phase 1 greenfield expansion of bromine derivative plant at Jhagadia (subsidiary Acume Chemicals) commissioned in March 2024; focuses on bromine performance derivatives and clear brine fluids. Additional Phase 1 expansion with new product portfolio expected by end of H1 FY '25; includes industrial bromine derivatives for oil & gas drilling, agrochemical intermediates, and petrochemical chain products. Total Phase 1 capex spent approx. INR 130-140 crores, with an additional INR 30-40 crores to complete Phase 1 pipeline. Phase 2 (focused on flame retardants - FR products) planned for secon

Future growth expectations in sales/revenue/volumes?

FY'25 volume growth expected at least 30% over FY'24. Bromine volume target for FY'25 is around 28,000 to 29,000 tons, with stronger sales in the second half. Revenue from Phase 1 bromine derivatives expected between INR 200 to 250 crores in FY'25, ramping up post first quarter. Phase 1 includes 15,000 to 20,000 tons production capacity for derivatives in first year. SOP (Sulphate of Potash) expected to contribute meaningfully from H2 FY'25, with second-grade SOP production started. Industrial Salt volumes expected to grow over FY'24 levels. Phase 2 bromine derivatives (flame retardants) comme

Current/ Expected Orderbook/ Pending Orders?

The company has a full order book for its bromine capacity planned for FY '25. Demand normalization and volume stabilization are currently happening with large order commitments per customer. Approximately 60-plus clients are engaged for bromine derivative products, with 10 clients having approved samples and 20-30 under testing. For Oren Hydrocarbon, order placement is expected before capital expenditure for refurbishing and restarting plants, with revenue in FY '25 expected between INR100 crores to INR250 crores, indicating ongoing order finalizations. The subsidiary Acume has starte

Archean ChemicalQ4 FY24Chemicals & Petrochemicals

Archean Chemical Q4 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹475P/E: 61.5Market Cap: ₹6.0K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 2

FY'25 volume growth expected at least 30% over FY'24.
Bromine volume target for FY'25 is around 28,000 to 29,000 tons, with stronger sales in the second half.
Revenue from Phase 1 bromine derivatives expected between INR 200 to 250 crores in FY'25, ramping up post first quarter.
Phase 1 includes 15,000 to 20,000 tons production capacity for derivatives in first year.
SOP (Sulphate of Potash) expected to contribute meaningfully from H2 FY'25, with second-grade SOP production started.
Industrial Salt volumes expected to grow over FY'24 levels.
Phase 2 bromine derivatives (flame retardants) commercialization anticipated by 1H FY'25 – timing is under evaluation.
Oren Hydrocarbon plant restart expected to generate INR 100 to 250 crores revenue in FY'25 with partial operation (2-3 quarters).
Bromine consumption in derivatives at peak Phase 1 utilization expected around 10,000–15,000 tons.

Margin guidance

Category 3

Archean Chemical Industries Limited expects healthy growth in FY '25, particularly from the Bromine segment, driven by stable demand and long-term contracts.
Revenue from the new Phase 1 bromine derivatives is anticipated between INR 200 to 300 crores, expecting to reach the higher end by year-end.
The Oren Hydrocarbon subsidiary is forecasted to contribute conservatively between INR 100 to 250 crores in FY '25, with potential upside based on market conditions and ramp-up.
The company targets approximately 30% volume growth for FY '25 over FY '24, supported by expansion in bromine derivatives and salt volumes.
EBITDA margin in FY '24 was strong at around 37%, with returns on capital employed near 24%, indicating operational efficiency likely to sustain.
The Phase 2 plant commissioning is expected in H1 FY '25, which could further boost revenue and profits beyond current estimates.
Integration and ramp-up of downstream bromine derivatives anticipate internal bromine consumption of 10,000-15,000 tons at peak Phase 1 utilization.

See what Archean Chemical management said on margin guidance — free account, 30 seconds.

Fundraise plans

The management mentioned that the money for Phase 2 capex, especially for the FR-related project, has already been raised and is available with the company.
They have taken a pause on committing further capex for Phase 2 to time it correctly according to market conditions.
There is no indication of immediate new fundraising through debt or equity in the current call.
The company is focusing on utilizing the capex already spent on Phase 1 and expanding the product portfolio within that.
Further capital expenditures will be assessed based on market developments and product pricing, with no explicit mention of new fundraising plans for the near term.

Order book

Yes

The company has a full order book for its bromine capacity planned for FY '25.
Demand normalization and volume stabilization are currently happening with large order commitments per customer.
Approximately 60-plus clients are engaged for bromine derivative products, with 10 clients having approved samples and 20-30 under testing.
For Oren Hydrocarbon, order placement is expected before capital expenditure for refurbishing and restarting plants, with revenue in FY '25 expected between INR100 crores to INR250 crores, indicating ongoing order finalizations.
The subsidiary Acume has started exports of bromine derivatives, signaling early orders and sales in that segment.
Overall, healthy demand visibility is reported for FY '25 from both domestic and export markets.

See what Archean Chemical management said on order book — free account, 30 seconds.

Capex plans

Yes

Phase 1 greenfield expansion of bromine derivative plant at Jhagadia (subsidiary Acume Chemicals) commissioned in March 2024; focuses on bromine performance derivatives and clear brine fluids.
Additional Phase 1 expansion with new product portfolio expected by end of H1 FY '25; includes industrial bromine derivatives for oil & gas drilling, agrochemical intermediates, and petrochemical chain products.
Total Phase 1 capex spent approx. INR 130-140 crores, with an additional INR 30-40 crores to complete Phase 1 pipeline.
Phase 2 (focused on flame retardants - FR products) planned for second half of FY '25, but currently on hold to optimize use of Phase 1 capex and evaluate market pricing for FR products.
Work started to refurbish and restart Oren Hydrocarbon plant (acquired via wholly owned subsidiary Idealis Chemicals); pending NCLT approvals with anticipated revenue between INR 100-250 crores in FY '25.
No specific timeline for further capex on flow battery R&D or power electronics subsidiary (Sicsem Pvt Ltd); updates to follow as projects mature.

Track Archean Chemical — get its next earnings analysis in your feed

How does Archean Chemical rank vs peers in Chemicals & Petrochemicals?

Pro feature

ThisArchean Chemical

Rev 2Mar 3

See where Archean Chemical sits in Chemicals & PetrochemicalsSee which companies these are, and every other name in the sector.Open rankings

How does Archean Chemical rank in Chemicals & Petrochemicals?

Compare Archean Chemical against every Chemicals & Petrochemicals company (Q4 FY24) on revenue, margins and earnings-call signals.

View Chemicals & Petrochemicals leaderboard →

What Archean Chemical's management said in earlier quarters

Others in Chemicals & Petrochemicals this season

Prasol Chemicals Ltd (Q1 FY27)
Q1 FY27 Revenue from Operations: ₹433.6 crores . Key investor presentation takeaways from Prasol Chemicals Ltd's Q1 FY27 investor presentation — and how it rank
Vipul Organics Ltd (Q4 FY26)
Q4 FY26 (Mar 2026) total revenue: ₹5,262.37 lakhs (Consolidated) . Key concall takeaways from Vipul Organics's Q4 FY26 earnings call — and how it ranks against…
Vipul Organics Ltd (Q1 FY27)
Q1 FY27 net revenue: ₹51.78 crore, up +37.7% YoY (Page 13) . Key concall takeaways from Vipul Organics's Q1 FY27 earnings call — and how it ranks against…
Fine Organic Industries Ltd (Q1 FY27)
Revenue from Operations (Consolidated) for Q1FY27: Rs 694.2 Cr, up 18.0% YoY from Rs 588.4 Cr in Q1FY26 (Page 34). Key concall takeaways from Fine Organic…

Compare:vs Solar Industries India Ltd vs Pidilite Inds.vs SRF Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →